Data compiled by Redley Lamar · ChainSifter Intelligence
11Suppliers
5Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Savara Inc. (SVRA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
20Total relationships
6Distinct source URLs
13High confidence
0.814Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Savara Inc. Suppliers
Ticker
Name
Confidence
Evidence
ML7-YARDLEY-PARTNERS-LP
ML7-YARDLEY-PARTNERS-LP
92%
On March 10, 2026, Savara Inc. (the “Company”) entered into an Agreement of Lease (the “Lease”) with ML7 Yardley Partners, LP (“Landlord”), pursuant to which the Company will lease approximately 10,7…
PARI
PARI
92%
We also have a commercial supply agreement with PARI (the “PARI Supply Agreement”) related to the supply of the PARI eFlow ® Nebulizer System and related accessories for commercial use with our produ…
GEMA
GEMA
90%
the Company shall pay GEMA a royalty equal to low-single digits of the net sales in that country
Reciprocal relationship from HTGC graph: Reciprocal relationship from SVRA graph: The First Amendment reset the timing and conditions to the Company’s ability to draw up to $75 million of additional …
The First Amendment reset the timing and conditions to the Company’s ability to draw up to $75 million of additional term loans under the Loan Agreement, subject in each case to FDA approval of the C…
PARI-PHARMA-GMBH
PARI-PHARMA-GMBH
90%
the Company will owe PARI a royalty of three-and one-half percent (3.5 %) based on net sales
THIRD-PARTY-CMOS
THIRD-PARTY-CMOS
90%
For clinical and commercial supplies, if approved, we have supply agreements with third party CMOs for drug substance, finished drug product, drug delivery devices and other necessary components of o…
RTW-INVESTMENTS-LP
RTW-INVESTMENTS-LP
80%
The First Amendment grants the Lenders a first-priority perfected security interest in the Company’s intellectual property that will convert to a negative pledge if the Company terminates the Purchas…
SVB-LOAN
SVB-LOAN
80%
As of March 31, 2026, approximately $ 0.4 million of fees consisting of legal, commitment and facility charges, paid to the Lenders were capitalized
primary and secondary drug substance manufacturing partners. The primary drug substance manufacturer is GEMA Biotech S.A. (“GEMA”). In February 2024, we announced entry into a Master Services Agreeme…
Reciprocal relationship from TMO graph: Reciprocal relationship from SVRA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SVRA graph: Reciprocal relationship from TMO grap…
Reciprocal relationship from HTGC graph: Reciprocal relationship from SVRA graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from SVRA graph: Reciprocal relationship from HTGC g…
we may establish; • the number of clinical and nonclinical studies necessary to demonstrate acceptable evidence of the safety and efficacy of our product candidate; • changes in standards of care whi…
NOBELPHARMA-CO-LTD
NOBELPHARMA-CO-LTD
62%
ze MOLBREEVI could be adversely impacted. Any new manufacturer or supplier would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applica…
OVERVIEW-SAVARA-INC
OVERVIEW-SAVARA-INC
62%
Item 1A. Risk Factors in this report. Overview Savara Inc. (together with its subsidiaries “Savara,” the “Company,” “we,” “our” or “us”) is a clinical-stage biopharmaceutical company focused on rare …
PARTNER-THERAPEUTICS-INC
PARTNER-THERAPEUTICS-INC
62%
ze MOLBREEVI could be adversely impacted. Any new manufacturer or supplier would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applica…
Savara Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SVRA-DEBT-12838
Warrants outstanding: 48678005
90%
xbrl warrant detail from xbrl 2026-03-31.
SVRA-DEBT
Debt stack $30.1M
90%
Market cache reports total debt of $30.1M.
SVRA-DEBT-12839
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-12-31.
Savara Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Savara Inc..
Savara Inc. Ownership
Holder
Name
Confidence
Evidence
SVRA-OWNER-NEA-MANAGEMENT-COMPANY-LLC
NEA Management Company, LLC
90%
13F overlay lists NEA Management Company, LLC as top holder; 187 tracked holders.
